Lyell Immunopharma (LYEL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.12, -0.85% vs the prior close of $8.19.
- Volume 194.96K shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LYEL dips 0.9% to $8.12. Closed at $8.12, -0.85% vs the prior close of $8.19. Day range $7.92–$8.44, opened at $8.24.
LYEL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — LYEL dips 0.9% to $8.12
- Closed at $8.12, -0.85% vs the prior close of $8.19. Day range $7.92–$8.44, opened at $8.24.
- Volume was 194.96K shares, 1.3x its 50-day average of 148.02K.
- Price is -32.1% vs its 50-day average ($11.96) and -54.0% vs its 200-day average ($17.66).
- 52-week range $7.20–$45.00; today's close sits at 2% of that range, 82.0% below the 52-week high.
Oct 15, 2026 — LYEL rises 2.5% to $8.19 on 2.1x normal volume
- Closed at $8.19, +2.50% vs the prior close of $7.99. Day range $7.76–$8.44, opened at $8.00.
- Volume was 325.00K shares, 2.1x its 50-day average of 151.21K — unusually heavy trading.
- Price is -32.2% vs its 50-day average ($12.08) and -53.9% vs its 200-day average ($17.78).
- 52-week range $7.20–$45.00; today's close sits at 3% of that range, 81.8% below the 52-week high.
Oct 14, 2026 — LYEL jumps 6.4% to $7.99 on 2.7x normal volume
- Closed at $7.99, +6.39% vs the prior close of $7.51. Day range $7.20–$8.28, opened at $7.42.
- Volume was 402.20K shares, 2.7x its 50-day average of 146.90K — unusually heavy trading.
- Price is -34.4% vs its 50-day average ($12.19) and -55.4% vs its 200-day average ($17.92).
- 52-week range $7.20–$45.00; today's close sits at 2% of that range, 82.2% below the 52-week high.
Oct 13, 2026 — LYEL slides 9.2% to $7.51, a 52-week low, 3 down days in a row
- Closed at $7.51, -9.19% vs the prior close of $8.27. Day range $7.39–$8.27, opened at $8.27.
- Volume was 187.20K shares, 1.3x its 50-day average of 144.88K.
- Price is -38.9% vs its 50-day average ($12.30) and -58.4% vs its 200-day average ($18.06).
- 52-week range $7.39–$45.00; today's close sits at 0% of that range, 83.3% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — LYEL slides 5.1% to $8.27, a 52-week low
- Closed at $8.27, -5.05% vs the prior close of $8.71. Day range $8.23–$8.69, opened at $8.63.
- Volume was 100.40K shares, 0.7x its 50-day average of 145.41K.
- Price is -33.3% vs its 50-day average ($12.41) and -54.6% vs its 200-day average ($18.21).
- 52-week range $8.21–$45.00; today's close sits at 0% of that range, 81.6% below the 52-week high.
Oct 9, 2026 — LYEL dips 0.9% to $8.71
- Closed at $8.71, -0.91% vs the prior close of $8.79. Day range $8.61–$9.10, opened at $8.72.
- Volume was 106.80K shares, 0.7x its 50-day average of 147.23K.
- Price is -30.3% vs its 50-day average ($12.50) and -52.5% vs its 200-day average ($18.36).
- 52-week range $8.21–$45.00; today's close sits at 1% of that range, 80.6% below the 52-week high.
Oct 8, 2026 — LYEL rises 2.7% to $8.79
- Closed at $8.79, +2.69% vs the prior close of $8.56. Day range $8.21–$8.85, opened at $8.49.
- Volume was 194.70K shares, 1.3x its 50-day average of 147.31K.
- Price is -30.2% vs its 50-day average ($12.60) and -52.5% vs its 200-day average ($18.50).
- 52-week range $8.21–$45.00; today's close sits at 2% of that range, 80.5% below the 52-week high.
Oct 7, 2026 — LYEL dips 0.6% to $8.56, a 52-week low, 5 down days in a row
- Closed at $8.56, -0.58% vs the prior close of $8.61. Day range $8.38–$8.95, opened at $8.48.
- Volume was 184.70K shares, 1.3x its 50-day average of 146.76K.
- Price is -32.5% vs its 50-day average ($12.68) and -54.0% vs its 200-day average ($18.62).
- 52-week range $8.38–$45.00; today's close sits at 0% of that range, 81.0% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — LYEL slides 5.1% to $8.61, a 52-week low, 4 down days in a row
- Closed at $8.61, -5.07% vs the prior close of $9.07. Day range $8.59–$9.13, opened at $9.13.
- Volume was 125.00K shares, 0.9x its 50-day average of 146.47K.
- Price is -32.6% vs its 50-day average ($12.77) and -54.1% vs its 200-day average ($18.74).
- 52-week range $8.59–$45.00; today's close sits at 0% of that range, 80.9% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — LYEL dips 2.1% to $9.07, a 52-week low, 3 down days in a row
- Closed at $9.07, -2.05% vs the prior close of $9.26. Day range $8.66–$9.31, opened at $9.27.
- Volume was 129.40K shares, 0.9x its 50-day average of 145.70K.
- Price is -29.5% vs its 50-day average ($12.86) and -51.9% vs its 200-day average ($18.86).
- 52-week range $8.66–$45.00; today's close sits at 1% of that range, 79.8% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — LYEL dips 1.6% to $9.26, a 52-week low
- Closed at $9.26, -1.59% vs the prior close of $9.41. Day range $9.21–$9.56, opened at $9.55.
- Volume was 111.40K shares, 0.8x its 50-day average of 145.30K.
- Price is -28.4% vs its 50-day average ($12.93) and -51.2% vs its 200-day average ($18.98).
- 52-week range $9.21–$45.00; today's close sits at 0% of that range, 79.4% below the 52-week high.
LYEL latest news & SEC filings
Every SEC filing by or about LYEL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Aguirre Jarrad Mattieu sold 422 shares at $8.63 (≈$3.64K) on Oct 12, 2026; now holds 19,857
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shook David sold 500 shares at $12.70 (≈$6.35K) on Sep 10, 2026
- Shook David sold 500 shares at $12.70 (≈$6.35K) on Sep 10, 2026
- Shook David sold 500 shares at $12.70 (≈$6.35K) on Sep 10, 2026
- Shook David sold 500 shares at $12.70 (≈$6.35K) on Sep 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Seely Lynn sold 9,589 shares at $15.54 (≈$149.01K) on Aug 21, 2026
- Seely Lynn sold 9,589 shares at $15.54 (≈$149.01K) on Aug 21, 2026
- Seely Lynn sold 9,589 shares at $15.54 (≈$149.01K) on Aug 21, 2026
- Seely Lynn sold 9,589 shares at $15.54 (≈$149.01K) on Aug 21, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hill Stephen J. sold 989 shares at $15.54 (≈$15.37K) on Aug 21, 2026
- Hill Stephen J. sold 989 shares at $15.54 (≈$15.37K) on Aug 21, 2026
- Hill Stephen J. sold 989 shares at $15.54 (≈$15.37K) on Aug 21, 2026
- Hill Stephen J. sold 989 shares at $15.54 (≈$15.37K) on Aug 21, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $4.00K (prior year $8.00K) (-50.0% vs Jun 30, 2025)
- Net income: -$44.76M (prior year -$42.68M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.92 (prior year -$2.89) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 21, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Jul 17, 2026 · Form CORRESP — Company letter to the SEC
Company letter to the SEC
Jul 16, 2026 · Form UPLOAD — SEC staff letter to the company
SEC staff letter to the company
Jul 13, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade LYEL
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 12, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.98% (largest 9.2%).
- Liquidity: about 169.48K shares (≈$1.38M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.12 vs a range of $7.20–$45.00 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Jun 2, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: David Shook sold 500 shares on Sep 10, 2026.
- Latest filings: 8-K Sep 10, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 24.51M shares outstanding (Aug 3, 2026), +27.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LYEL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.24 | 8.44 | 7.92 | 8.12 | 194.96K |
| Oct 15, 2026 | 8.00 | 8.44 | 7.76 | 8.19 | 325.00K |
| Oct 14, 2026 | 7.42 | 8.28 | 7.20 | 7.99 | 402.20K |
| Oct 13, 2026 | 8.27 | 8.27 | 7.39 | 7.51 | 187.20K |
| Oct 12, 2026 | 8.63 | 8.69 | 8.23 | 8.27 | 100.40K |
| Oct 9, 2026 | 8.72 | 9.10 | 8.61 | 8.71 | 106.80K |
| Oct 8, 2026 | 8.49 | 8.85 | 8.21 | 8.79 | 194.70K |
| Oct 7, 2026 | 8.48 | 8.95 | 8.38 | 8.56 | 184.70K |
| Oct 6, 2026 | 9.13 | 9.13 | 8.59 | 8.61 | 125.00K |
| Oct 5, 2026 | 9.27 | 9.31 | 8.66 | 9.07 | 129.40K |
| Oct 2, 2026 | 9.55 | 9.56 | 9.21 | 9.26 | 111.40K |
| Oct 1, 2026 | 9.80 | 9.97 | 9.36 | 9.41 | 115.20K |
| Sep 30, 2026 | 9.61 | 10.00 | 9.43 | 9.79 | 153.90K |
| Sep 29, 2026 | 9.74 | 9.74 | 9.44 | 9.63 | 140.80K |
| Sep 28, 2026 | 9.80 | 9.96 | 9.60 | 9.74 | 129.00K |
| Sep 25, 2026 | 10.16 | 10.16 | 9.81 | 9.85 | 108.90K |
| Sep 24, 2026 | 10.41 | 10.76 | 10.06 | 10.12 | 164.50K |
| Sep 23, 2026 | 11.05 | 11.05 | 10.32 | 10.53 | 161.50K |
| Sep 22, 2026 | 11.09 | 11.23 | 10.94 | 11.15 | 211.50K |
| Sep 21, 2026 | 11.02 | 11.18 | 10.60 | 10.93 | 142.60K |
About Lyell Immunopharma
Lyell Immunopharma (LYEL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1806952.
LYEL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Otis W Brawley | Director | Jun 12, 2026 |
| Mark Bachleda | Director | Jun 12, 2026 |
| Cathy Friedman | Director | Jun 12, 2026 |
| Richard Klausner | Director | Jun 12, 2026 |
| Elizabeth G Nabel | Director | Jun 12, 2026 |
| William Jl Rieflin | Director | Jun 12, 2026 |
| Sumant Ramachandra | Director | Jun 12, 2026 |
| Lynn Seely | President and CEO | Aug 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jarrad Mattieu Aguirre | Chief Medical Officer | Sep 10, 2026 |
| Veronica Sanchez Bulis | VP, Corporate Controller | Aug 11, 2026 |
| Stephen J. Hill | Chief Operating Officer | Aug 25, 2026 |
| Gary K. Lee | Chief Scientific Officer | Aug 25, 2026 |
| Mark A Meltz | General Counsel | Feb 11, 2026 |
| Lynn Seely | President and CEO | Aug 25, 2026 |
| Smital Shah | Chief Fin. and Bus. Officer | Mar 16, 2026 |
| David Shook | Chief Medical Officer | Sep 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | David Shook | Sale | 500 | $12.70 |
| Sep 10, 2026 | David Shook | Sale | 500 | $12.70 |
| Sep 10, 2026 | David Shook | Sale | 500 | $12.70 |
| Sep 10, 2026 | David Shook | Sale | 500 | $12.70 |
| Aug 21, 2026 | Lynn Seely | Sale | 9,589 | $15.54 |
| Aug 21, 2026 | Lynn Seely | Sale | 9,589 | $15.54 |
| Aug 21, 2026 | Lynn Seely | Sale | 9,589 | $15.54 |
| Aug 21, 2026 | Lynn Seely | Sale | 9,589 | $15.54 |
| Aug 21, 2026 | Stephen J. Hill | Sale | 989 | $15.54 |
| Aug 21, 2026 | Stephen J. Hill | Sale | 989 | $15.54 |
| Aug 21, 2026 | Stephen J. Hill | Sale | 989 | $15.54 |
| Aug 21, 2026 | Stephen J. Hill | Sale | 989 | $15.54 |
| Aug 21, 2026 | Gary K. Lee | Sale | 1,457 | $15.54 |
| Aug 21, 2026 | Gary K. Lee | Sale | 1,457 | $15.54 |
| Aug 21, 2026 | Gary K. Lee | Sale | 1,457 | $15.54 |
LYEL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $36.00K | $-274.45M | -16.06 | $-150.02M |
| Dec 31, 2024 | $61.00K | $-342.99M | -26.23 | $-162.39M |
| Dec 31, 2023 | $130.00K | $-234.63M | -18.70 | $-163.69M |
| Dec 31, 2022 | $84.68M | $-183.12M | -0.74 | $-169.56M |
| Dec 31, 2021 | $10.65M | $-250.22M | -1.84 | $-126.25M |
Latest balance sheet: total assets $311.15M, total liabilities $77.34M, cash $72.98M (as of Jun 30, 2026).
LYEL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $14.21 |
| May 6, 2026 | 8-K Item 2.02 (results) | $20.85 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $24.77 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $17.63 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $10.57 |
| May 13, 2025 | 8-K Item 2.02 (results) | $8.10 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $13.32 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $24.40 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on LYEL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.